Novel Genetically Engineered Tetracenomycins

Genetically engineered hybrid strains, in which the genes of the urdamycin‐producer Streptomyce fradiae are combined with some of the biosynthetic genes of the elloramycin‐producer Streptomyces olivaceus or the genes of the tetracenomycin‐producer Streptomyces glaucescens, assemble novel hybrid antibiotics of the tetracenomycin type. The results prove that this combinatorial biosynthesis method may be a useful alternative for the production of new natural products which can then be screened.